Clinical trials: Juvenile Idiopathic Arthritis, open to volunteers
Polyarticular Course Juvenile Idiopathic Arthritis (JIA)
Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis
This study is an open-label, randomized, multicenter trial that incorporates a multi-arm design comparing each of 3 non-TNFi (Tumor Necrosis Factor inhibitor) medications to a second TNFi (active control) within a sequential…
- Trial name
- SMART-JIA (NCT06654882)
- Testing
- TNFi (Tumor Necrosis Factor inhibitor) medication, Abatacept, Tocilizumab
- Where
- 7 sites in United States, Germany and 2 more
- Volunteers
- 400 people
- Sponsor
- Duke University
Systemic Juvenile Idiopathic Arthritis, Lung Diseases
Pulmonary Involvement in Children With Systemic JIA
This cross-sectional study aims to describe the clinical characteristics of pulmonary involvement in children with systemic juvenile idiopathic arthritis.
- Trial name
- NCT07882381
- Volunteers
- 30 people
- Sponsor
- Assiut University
Juvenile Idiopathic Arthritis (JIA)
Development of a Multidimensional Prediction Model for the Course and Outcome of Early-Onset Juvenile Idiopathic Arthritis (JIA)
This is a prospective-retrospective, translational, no profit, multicentric, observational study. A cohort of at least 100 early-onset JIA patients attending the Unit of Rheumatology and Autoinflammatory Diseases, Department of…
- Trial name
- NCT07882667
- Where
- 2 sites in Italy
- Volunteers
- 130 people
- Sponsor
- Istituto Giannina Gaslini
Juvenile Idiopathic Arthritis
A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)
Primary Objective: To describe the pharmacokinetic (PK) profile of sarilumab in patients aged 1-17 years with Systemic Juvenile Idiopathic Arthritis (sJIA) in order to identify the dose and regimen for adequate treatment of this…
- Trial name
- SKYPS (NCT02991469)
- Testing
- Sarilumab SAR153191 (REGN88)
- Where
- 40 sites in Argentina, Canada and 12 more
- Volunteers
- 51 people
- Sponsor
- Sanofi
Juvenile Idiopathic Arthritis
Optimizing Treatment for Patients With Juvenile Idiopathic Arthritis in Sustained Remission: The MOVE-JIA Trial
The goal of this clinical trial is to compare three different maintenance and step-down treatment strategies in children and adolescents with juvenile idiopathic arthritis in sustained remission.
- Trial name
- MOVE-JIA (NCT06653634)
- Testing
- Methotrexate, TNF Inhibitor
- Where
- 7 sites in Norway
- Volunteers
- 150 people
- Sponsor
- Oslo University Hospital
Juvenile Idiopathic Arthritis (JIA), Fibromyalgia
Biopsychosocial Risk Influences on the Development and Generation of Early-Onset Chronic Pain
The purpose of the study is to discover the underlying subtypes of chronic musculoskeletal pain (muscle and joint pain) in youth.
- Conditions
- Juvenile Idiopathic Arthritis (JIA), Fibromyalgia, Lupus, Scoliosis
- Trial name
- BRIDGE Pain (NCT07602595)
- Testing
- Not applicable- observational study
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Juvenile Idiopathic Arthritis, Children
M3-JIA: Making Mindfulness Matter for Children With JIA
The investigator will evaluate the efficacy of M3©, an intervention for patients with JIA and their caregivers. Children with Juvenile arthritis and their parents will attend an 8 week online program called Making Mindfulness…
- Conditions
- Juvenile Idiopathic Arthritis, Children, Mental Health, Mental Well-being
- Trial name
- M3-JIA (NCT06376149)
- Testing
- M3 Intervention group, M3 Waitlist Group
- Where
- 3 sites in Canada
- Volunteers
- 74 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Juvenile Idiopathic Arthritis
A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
The reason for this study is to see if the study drug baricitinib is safe and effective in the treatment of JIA in participants ages 1 to 17.
- Trial name
- JUVE-X (NCT03773965)
- Testing
- Baricitinib
- Where
- 78 sites in Argentina, Australia and 18 more
- Volunteers
- 190 people
- Sponsor
- Eli Lilly and Company
Autoimmune Diseases, Lupus Erythematosus, Systemic
Comparative Autoantibody and Immunologic Cell Marker Study
The purpose of this study is to compare immune phenotype, function, and specificity of B lymphocytes from different developmental stages in autoimmune patients to B cells from infectious disease patients and healthy controls.
- Conditions
- Autoimmune Diseases, Lupus Erythematosus, Systemic, Communicable Diseases
- Trial name
- NCT02422875
- Where
- 3 sites in United States
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Emory University
Refractory Systemic Juvenile Idiopathic Arthritis, Systemic Juvenile Idiopathic Arthritis
Allogeneic Hematopoietic Cell Transplantation for Refractory Systemic Juvenile Idiopathic Arthritis.
The goal of this study is to collect clinical data and samples and to evaluate the feasibility of allogeneic hematopoietic cell transplantation (HCT) in children and young adults with refractory Systemic Juvenile Idiopathic…
- Conditions
- Refractory Systemic Juvenile Idiopathic Arthritis, Systemic Juvenile Idiopathic Arthritis, Systemic Juvenile Idiopathic Arthritis Associated Lung Disease
- Trial name
- NCT07845942
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Active Systemic Juvenile Idiopathic Arthritis
To Evaluate the Efficacy and Safety of Genalumab for Injection in the Treatment of Active Systemic Juvenile Idiopathic Arthritis.
A multicenter, randomized Phase II/III clinical study to evaluate the efficacy and safety of GenaKumab in the treatment of active systemic juvenile idiopathic arthritis.
- Trial name
- NCT05925452
- Testing
- GenaKumab
- Where
- 10 sites in China
- Volunteers
- 290 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Juvenile Idiopathic Arthritis
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
Juvenile Idiopathic Arthritis (JIA) is the most common type of arthritis that affects children. The term "idiopathic" means "of unknown origin".
- Trial name
- SELECT-sJIA (NCT05609630)
- Testing
- Upadacitinib, Tocilizumab
- Where
- 45 sites in United States, Argentina and 15 more
- Volunteers
- 90 people
- Sponsor
- AbbVie
Systemic Juvenile Idiopathic Arthritis (sJIA), Systemic Juvenile Idiopathic Arthritis
Clinical Features and Treatment of Systemic JIA in Children
This study aims to describe the clinical features, disease patterns, and different treatment modalities used in children with systemic juvenile idiopathic arthritis (sJIA).
- Trial name
- CST-SJIA (NCT07814963)
- Testing
- Tocilizumab (Actemra®)
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Sohag University
Juvenile Idiopathic Arthritis
Oral Health, Saliva Bacteria, and Disease Activity in Children With JIA: A Cross-Sectional Study.
The goal of this observational study is to learn about the relationship between disease activity and oral health status in children with juvenile idiopathic arthritis (JIA).
- Trial name
- JIA (NCT07799831)
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Rheumatic Diseases, Arthritis
Pain-Sleep in Rheumatic Disease
Overall, our understanding of how pain and sleep are experienced and how they can be treated in teenagers with rheumatic diseases is limited.
- Conditions
- Rheumatic Diseases, Arthritis, Lupus, Lupus Arthritis, Systemic Lupus Erythematosus
- Trial name
- NCT07775612
- Testing
- Better Nights, Better Days for Youth
- Volunteers
- 43 people
- Sponsor
- The Hospital for Sick Children
Juvenile Idiopathic Arthritis (JIA)
OLE Study With Filgotinib in JIA
This OLE study is designed to evaluate long-term safety, tolerability, and efficacy of filgotinib in patients with polyarticular or systemic juvenile idiopathic arthritis (pJIA-sJIA) who have completed the treatment…
- Trial name
- OLE JIA (NCT07553182)
- Testing
- Filgotinib
- Where
- 4 sites in France, Germany and 1 more
- Volunteers
- 80 people
- Sponsor
- Alfasigma S.p.A.
Pericarditis, Tako-TSUBO Cardiomyopathy
Inflammatory Disease Biobank for Immunophenotyping and Cardiovascular Research
INFLAME-BANK is a French multicenter prospective observational ancillary study of the international EACVI-INFLAME project. It aims to establish a biobank and perform immunophenotyping and proteomic analyses in patients with…
- Conditions
- Pericarditis, Tako-TSUBO Cardiomyopathy, Myocarditis, Inflammatory Cardiomyopathies
- Trial name
- INFLAME-BANK (NCT07737470)
- Volunteers
- 300 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Psoriatic Arthritis, Juvenile, Polyarticular Juvenile Idiopathic Arthritis
Korea Xeljanz Post-marketing Surveillance for Juvenile Idiopathic Arthritis
This study is to assess the safety and effectiveness of Xeljanz in Juvenile Idiopathic Arthritis (JIA) patients in routine clinical practice in Korea. JIA patients experience persistent joint pain, swelling and stiffness.
- Trial name
- KRXeljanzJIA (NCT05754710)
- Testing
- Xeljanz
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- Pfizer
Arthritis, Juvenile, Arthritis, Childhood
Feasibility of a Diet Intervention for Juvenile Arthritis
Families of children with arthritis are highly interested in the benefits of diet to improve their child's disease and future health outcomes.
- Conditions
- Arthritis, Juvenile, Arthritis, Childhood, Juvenile Idiopathic Arthritis
- Trial name
- DIGEST-JA (NCT06474546)
- Testing
- Diet intervention
- Where
- 7 sites in Canada
- Volunteers
- 54 people
- Sponsor
- The Hospital for Sick Children
Juvenile Idiopathic Arthritis, Systemic Lupus Erythematosus
Development of a Therapeutic Endpoint in Pediatric Rheumatologic Conditions
The overarching goal of this study is the development of a physiologic endpoint of pain and treatment effect in three distinct rheumatology populations.
- Conditions
- Juvenile Idiopathic Arthritis, Systemic Lupus Erythematosus, Fibromyalgia
- Trial name
- NCT04833465
- Testing
- No Intervention
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Children's National Research Institute